All In Biotech

Drug Trial Radar · NCT00900146

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study

Last checked: Nov 20, 2026Latest source record: Feb 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 556 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

556

Actual

Start

Apr 2009

Primary completion

Nov 2010

Study completion Nov 2010

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
May 12, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of patients with Type 2 diabetes mellitus (T2DM) already treated on maximum dose metformin.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • CanakinumabDrug

    Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.

  • MetforminDrug

    Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.

  • PlaceboDrug

    Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events, Death and Clinical Significant AEs During 4 Months (Period II)Time frame: 4 months (Period II)
  2. Change From Baseline in Hemoglobin A1c (HbA1c) at Month 4 During Dose-finding Period of the Study (Period II)Time frame: Baseline, Month 4
  3. Change From Baseline in Dynamic Phase Secreted Insulin Per Unit of Glucose Concentration (Φd) Over 4 Months (Period III)Time frame: Baseline, Over Month 4

Locations

106 sites in 14 countries. Site status is shown where the registry gives one.

  • Anasazi Internal Medicine

    Phoenix, Arizona

  • Whittier Institute of Diabetes

    La Jolla, California

  • Novartis Investigative Site

    Los Gatos, California

  • Novartis Investigative Site

    Santa Monica, California

  • Orange County Research Center

    Tustin, California

  • Novartis Investigative Site

    Atlanta, Georgia

  • Deaconess Clinic

    Evansville, Indiana

  • Novartis Investigative Site

    Jackson, Mississippi

  • Novartis Investigative Site

    Picayune, Mississippi

  • Novartis Investigative Site

    Trenton, New Jersey

  • Diabetes Research Center

    Columbus, Ohio

  • Tri-State Medical Group

    Beaver, Pennsylvania

  • Preferred Primary Care Physicians

    Pittsburgh, Pennsylvania

  • Novartis Investigative Site

    Columbia, South Carolina

  • R/D Clinical Research

    Lake Jackson, Texas

  • Novartis Investigative Site

    Pasadena, Texas

  • Novartis Investigative Site

    San Antonio, Texas

  • Medical Research Initiatives Inc

    Virginia Beach, Virginia

  • Novartis Investigative Site

    Rosario Santa Fe, Argentina

  • DIM Clinica Privada

    Buenos Aires, Buenos Aires, Argentina

  • Centro Medico Viamonte

    Buenos Aires, Buenos Aires, Argentina

  • Consultorios Asociados de Endocrinologia

    Buenos Aires, Buenos Aires, Argentina

  • Clinica de Fracturas y Ortopedia

    Mar del Plata, Buenos Aires, Argentina

  • Hospital Juan Ramon Vidal

    Corrientes, Corrientes Province, Argentina

  • Instituto de Investigaciones Biomedicas

    Santa Fe, Santa Fe Province, Argentina

  • Centro de Investigaciones Clinicas del Litoral

    Santa Fe, Santa Fe Province, Argentina

  • Private Practice - DEMEULEMEESTER

    Gozée, Belgium

  • Novartis Investigative Site

    Heist-op-den-Berg, Belgium

  • UZ Brussel

    Jette, Belgium

  • Novartis Investigative Site

    Hong Kong, China

  • Praxis F. Franzmann

    Bad Oeynhausen, Germany

  • emovis GmbH

    Berlin, Germany

  • Praxis Dr. Stütz

    Bretten, Germany

  • GWT-TUB GmbH

    Dresden, Germany

  • Gemeinschaftspraxis und Dialysezentrum Karlstraße

    Düsseldorf, Germany

  • Asklepios Klinik St. Georg

    Hamburg, Germany

  • Städt. Kankenhaus Nordstadt

    Hanover, Germany

  • Diabeteszentrum Hohenmölsen

    Hohenmölsen, Germany

  • Johannes Gutenberg-Universität Mainz

    Mainz, Germany

  • Zentrum für Klinische Forschung Neuwied (ZKSN)

    Neuwied, Germany

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.